Featured | Mount Sinai Today

What Are the New FDA-Approved BEMT Sunscreens?

Updated on Jul 6, 2026 | Dermatology, Featured, Skin Health, Your Health

A woman applying sunscreen on a young child.

For more than 25 years, sunscreen ingredients available in the United States remained largely unchanged. That changed on June 9, 2026, when the Food and Drug Administration (FDA) approved bemotrizinol (BEMT), the first new sunscreen filter approved in the United States since 1999.

The approval is welcome news for dermatologists because BEMT offers another option for broad-spectrum sun protection against both UVA and UVB rays.

“I’m very excited that the FDA has approved this new filter,” says Nicholas Brownstone, MD, board certified dermatologist and Assistant Professor of Dermatology at the Icahn School of Medicine at Mount Sinai. “It’s time we have new filters because sunscreen technology continues to advance. We want to take advantage of the latest research and innovations to better protect our skin.”

So what is BEMT, and how does it compare with the sunscreens currently available over the counter? Dr. Brownstone explains.

Are BEMT sunscreens new?

Although BEMT is newly approved in the United States, it has been used safely for years in other parts of the world, including Europe, Asia, and Australia.

Unlike many other countries, the United States regulates sunscreen as an over-the-counter drug. As a result, approving new sunscreen ingredients has historically been a lengthy regulatory process.

Recent legislative changes, including provisions in the CARES Act, helped modernize parts of that process.

“As dermatologists, we welcome this innovation,” says Dr. Brownstone. “We hope it leads to continued advances in sunscreen technology.”

View this post on Instagram

A post shared by Mount Sinai Health System (@mountsinainyc)

Nicholas Brownstone, MD, board certified dermatologist and Assistant Professor of Dermatology at the Icahn School of Medicine at Mount Sinai, explains the newly approved BEMT sunscreens.

How does BEMT compare with existing sunscreens?

Bemotrizinol is a broad-spectrum chemical sunscreen filter, meaning a single ingredient helps protect against both UVA and UVB rays.

It is also highly photostable, meaning it maintains its effectiveness when exposed to sunlight better than many existing sunscreen filters.

Another advantage is that it allows manufacturers to create lighter, more cosmetically elegant sunscreen formulations without relying on as many additional ingredients.

The FDA has also determined that BEMT is generally recognized as safe and effective. Because its molecule is larger than those of many existing chemical sunscreen filters, it is less likely to be absorbed into the bloodstream.

How does BEMT compare with mineral sunscreens?

Mineral sunscreens remain an excellent option for protecting your skin.

Mineral sunscreens work by reflecting and scattering ultraviolet rays, while chemical sunscreens such as BEMT absorb ultraviolet energy before it can damage the skin.

One difference is cosmetic appearance. Mineral sunscreens may leave a white cast on the skin, while chemical sunscreens often blend in more easily.

Both mineral and chemical broad-spectrum sunscreens can provide effective sun protection when used correctly.

Why is broad-spectrum protection important?

Broad-spectrum sunscreen protects against both UVA and UVB rays.

UVA rays contribute primarily to premature skin aging and photoaging. UVB rays are the leading cause of sunburns and play a major role in the development of skin cancer.

Protecting against both types of ultraviolet radiation helps reduce the risk of sunburn, skin cancer, and premature skin aging.

Is my current sunscreen still good enough?

Yes—if your sunscreen is labeled “broad spectrum” and has an SPF of 30 or higher, it remains an effective choice when applied correctly.

Dr. Brownstone recommends:

Using an SPF 30 or higher broad-spectrum sunscreen
Applying about one shot glass of sunscreen to cover the body
Applying sunscreen about 15 minutes before going outdoors
Reapplying every two hours, or more often if you’re swimming or sweating

People often ask Dr. Brownstone which sunscreen is best.

His answer is simple: “The best sunscreen is the sunscreen that you’ll actually use.”

Administrative Fellowship Program Continues to Advance Future Health Care Leaders

Jun 30, 2026 | Community, Featured

As one chapter closes, another begins. The Mount Sinai Office for Health Data, Outcomes, and Engagement Strategy (HDOES) is proud to welcome Cassandra Felix, MHSA, MPH, who will join the Mount Sinai Health System as an Administrative Fellow in July.

Cassandra Felix

A graduate of the University of Michigan School of Public Health, Ms. Felix brings a passion for health care leadership, a dedicated focus on advancing patient-centered care, and a strong commitment to addressing the needs of underserved communities. The HDOES team is excited to welcome the perspective, energy, and purpose she will bring to the Health System.

“I am excited to collaborate with teams across Mount Sinai Health System to transform care delivery and improve outcomes for the communities we serve. This opportunity reflects my commitment to health equity and contributing to efforts that drive meaningful change in health care,” she says. Her passion for advancing health equity and improving outcomes aligns closely with Mount Sinai’s mission.

As HDOES welcomes its newest fellow, Tyler Nichols, MPH, who recently completed the Administrative Fellowship Program, has been appointed Associate Director of Site Administration for Mount Sinai Morningside and Mount Sinai West.

Since joining the fellowship in 2024, Mr. Nichols has demonstrated a commitment to leadership and operational excellence—approaching every challenge with thoughtfulness, integrity, and a clear dedication to the communities Mount Sinai serves. HDOES is proud of the leader he has become and excited to see the continued impact he will make in this important role.

Tyler Nichols

“The Administrative Fellowship has been one of the most meaningful and transformative experiences of my career. It provided me with the opportunity to engage with leaders, teams, and front-line staff across Mount Sinai, while contributing to both local priorities and systemwide initiatives that advance patient care and operational excellence,” he says. “I am blessed to continue my journey, working under the leadership of Janice Connolly, Vice President of Administration. I look forward to building on the foundation of the fellowship and continuing to support work that makes a lasting impact for our patients, workforce, and communities.”

Established in 2015 and managed by the Office for Health Data, Outcomes, and Engagement Strategy, the Administrative Fellowship Program is a two-year leadership development program designed for early-career professionals who are passionate about advancing health equity and addressing the needs of underserved communities. Through hands-on learning opportunities across administrative and clinical departments, fellows build the skills and relationships needed to become effective, equity-centered leaders—all in service of Mount Sinai’s commitment to health equity and excellence in care.

Learn more about Mount Sinai's Office for Health Data, Outcomes, and Engagement Strategy

Nursing Plays a Central Role as Mount Sinai Tisch Cancer Center Achieves Top Designation

Updated on Jun 26, 2026 | Featured, Nursing

From left: Jennifer Pouliot, MSN, RN, OCN; Frances Cartwright, PhD, RN-BC, AOCN, FAAN; Rita Jakubowski, DNP; and Jane Weisser, NP, AOM, P-BC

When the Mount Sinai Tisch Cancer Center (TCC) received its Comprehensive Cancer Center designation from the National Cancer Institute, it completed a comprehensive, 10-year review process that placed TCC among the top one percent of cancer centers nationwide. These centers dedicate significant resources to develop research programs, faculty, and facilities that promote better and innovative approaches to cancer prevention, diagnosis, and treatment.

At Mount Sinai, nursing plays a significant role.

“After a decade of growth in research, clinical trials, and community outreach, Mount Sinai became eligible to apply for Comprehensive Cancer Center designation in 2024,” says Frances Cartwright, PhD, RN-BC, AOCN, FAAN, Vice President of Nursing, Mount Sinai Health System Oncology Services, the Center for Nursing Research and Innovation, and Associate Professor of Medicine, Icahn School of Medicine at Mount Sinai. “Nursing has been an integral part of that rigor—developing practice standards for clinical trials, delivering high-quality care, standardizing practices and education to enhance safety, innovating to offer seamless care to patients throughout their care experience, and it goes on.”

For example, in the case of multiple myeloma research, clinical trials, and survivorship, Mount Sinai’s nursing leadership extends globally.

In 2017, Mount Sinai administered the first chimeric antigen receptor (CAR) T-cell therapy in myeloma, a groundbreaking cellular therapy that uses the patient’s own immune system to fight cancer.

“We treated the first human ever to receive this therapy,” says Donna Catamero, NP, DNP-c, OCN, CCRC, Associate Director of Myeloma Research, The Mount Sinai Hospital. “These patients had a three-year survival rate, and today we’re talking about how we define ‘cure.’ This dramatic progress is directly due to the clinical trials we conducted at Mount Sinai, and the care and treatment approaches our nurses developed are now literally the standard of care worldwide.”

“The role of nursing is crucial,” Dr. Catamero says. “We’re very closely linked to the patients throughout, overseeing their care, collecting and evaluating blood samples, managing adverse events. In so many ways, nursing serves as the backbone of these clinical trials.”

While the protocols for clinical trials vary significantly from one to another, Mount Sinai has established its own set of required quality and safety-driven standards to be met by every trial within the Health System.

“Mount Sinai sets the bar high,” says Ruth Knecht, MSN, RN, Nurse Clinician, The Mount Sinai Hospital. “It boils down to numerous multidisciplinary teams determining: Can we do this in a manner that is safe, maintain the integrity of the study, include all the resources we’ll we need—staffing, education, equipment—and adhere to Mount Sinai’s exacting standards.”

“Standardized workflows are vital,” Ms. Knecht says. “They ensure the consistency, predictability, reliability, and ultimately safety, of our clinical trials. For example, we’ve developed a standard study procedure checklist that must be followed for every study patient, every day. The nurses know exactly what they have to do at every encounter.”

Donna Catamero, NP, DNP-c, OCN, CCRC, left, and Ruth Knecht, MSN, RN

A complementary set of robust Health System-wide policies now applies to each entity throughout the Health System, including those that have the potential to administer aspects of clinical trials in the future.

Jennifer Pouliot, MSN, RN, OCN, Senior Director, Oncology Quality and Safety, Mount Sinai Health System, helped make this complex task a reality. She and her colleagues had a poster about their work accepted for the Oncology Nursing Society’s Annual Congress.

“We worked with an interdisciplinary team from across Mount Sinai to ensure we had crystal clear clinical trial guidelines,” Ms. Pouliot says. “Likewise, if and when we conduct clinical research at any Health System entity, the necessary policies would already be in place and applicable: how Pharmacy prepares the drug being investigated, how we measure nurses’ competency for research trials, etc. It was our job to ensure everyone involved was on the same page and supported at every step.”

The impact of nursing extends beyond completion of a clinical trial. For example, cancer patients who undergo a bone marrow transplant (BMT) also receive chemotherapy and immunosuppressive therapy. While potentially lifesaving, these treatments can put patients at risk for other health problems post-transplant.

The nurse-led BMT Survivorship Clinic at Mount Sinai offers these patients ongoing health care that is specific to their initial diagnosis—looking for early signs of graft-versus-host disease, secondary cancer, bone thinning, cardiac issues, thyroid function, and others—to enable cancer survivors to live a healthy life.

“In addition to their routine doctor visits, the BMT clinic nurses see patients at key milestones: 3, 6, and 12 months and then annually,” says Rita Jakubowski, DNP, Clinical Program Director and Founder, BMT Survivorship Clinic, The Mount Sinai Hospital. “This creates a critical bridge between the transplant and primary care doctors and offers patients significant peace of mind. We’re educating survivors about this next phase in their journey and ensuring that everyone involved in their care—including the patient—keenly understands what tests are being done, when, and why, and what we need to be especially vigilant about to avoid complications as each BMT patient progresses.”

Dr. Jakubowski’s work has gained widespread attention, and she was invited to present at the national Advanced Practice Providers Oncology Summit, an annual conference designed to highlight the latest evidence-based strategies to optimize care and outcomes for patients with cancer.

In the case of breast cancer patients, medical oncologists provide care for many years, through completion of their antiestrogen treatment. At this four-year mark, patients enter a new phase of their cancer journey and are referred to the Breast Cancer Survivorship Clinic.

“Our clinic nurses are in the middle lane of wellness and ensuring full-circle service,” says Jane Weisser, NP, AOM, P-BC, Clinical Program Manager, Breast Cancer Survivorship Clinic, Dubin Breast Center. “We operate a robust clinical program that specializes in the breast cancer survivor’s specific needs,” Ms. Weisser says, “including offering survivors a consistent and specialized clinician as their health care lead.”

Ms. Weisser also co-chaired a systemwide survivorship committee that is a cross section of various specialties: medical oncology, surgery, social work, psychiatry, chaplaincy, nutrition, therapeutic massage, and other providers involved in oncology. Her work is spreading throughout the Health System as a high-risk clinic and breast cancer survivorship care will soon be offered at a second site.

The Comprehensive Cancer Center designation of the Mount Sinai Tisch Cancer Center affirms a relentless dedication by so many—individuals and teams within multiple specialties and sites—to provide high-quality, safe, and innovative cancer care and treatment. And in the end, all of their time, care, attention to detail, and advocacy come together in every moment a patient receives care—always with a Mount Sinai nurse at their side.

Turning Health Administration Classroom Lessons Into Real-World Health Care Impact

Jun 9, 2026 | Featured, School

Titus Kong, MHA

Titus Kong, MHA, is an alumnus of the Master of Health Administration (MHA) program at the Icahn School of Medicine at Mount Sinai. The MHA program prepared him for a career as an Operations Supervisor in Mount Sinai’s Emergency Department.

Mr. Kong started his higher education journey studying Organizational Psychology at Baruch College. He completed his undergraduate degree in 2022 and began looking for Human Resources positions around New York City.

He worked as a line cook, waiter, and server at various restaurants, where he discovered that he enjoyed serving people. Mr. Kong’s next role was at Gentile Retina, an ophthalmology clinic run by the New York Eye and Ear Infirmary of Mount Sinai. He worked there for two years, gaining useful clinical experience. Mr. Kong enjoyed interacting with patients and found that they enjoyed his dedication to providing a positive care experience for them.

“I had a lot of fun interacting with the patients at Gentile Retina. They enjoyed the service and dedication that I provided. It felt fulfilling to address their needs and concerns.”

Mr. Kong wanted to expand his career and began looking into graduate programs. He noticed that the Icahn School of Medicine had an MHA program. He found that this program aligned with what he was looking for professionally. He discovered that some of the doctors he worked with were professors at Mount Sinai, which inspired him to apply. He only applied to the MHA program at the Icahn School of Medicine; he says it was that program or nothing.

Mr. Kong also has a personal connection to The Mount Sinai Hospital—he was born there.

Upon joining the program, Mr. Kong found two courses to be particularly impactful during his studies. The first was Health System Operations and Program Management, taught by Victoria Ellsworth, MHA, who now serves as his advisor. The course provided a comprehensive overview of health care operations across a variety of care settings, including inpatient and ambulatory operations, quality and safety, patient experience, supply chain management, health care facilities, emergency management, and the relationship between operations and finance. The course gave Mr. Kong a practical understanding of how different hospital departments work together, preparing him to coordinate teams and drive operational improvements in a fast-paced emergency care environment.

The second course that had a lasting impact on him was Population Health and Managed Care, taught by Robert Fields, MD, MHA. The course explored the ongoing shift toward population health management and value-based care across the U.S. health care system, examining the clinical, financial, organizational, and analytical strategies required for health care organizations to succeed in an evolving landscape. Through the course, Mr. Kong developed an understanding of health care utilization trends, value-based payment models, risk management, and the importance of delivering high-quality care while maintaining financial sustainability.

He appreciated how the MHA program paired each student with a mentor. His mentor was Maya Ayoubi, MHA, a former member of the Patient Operations Team at Mount Sinai. He was inspired by Ms. Ayoubi’s dedication to improving processes and her advice to him; say yes to everything and to take on challenges to gain experience. Mr. Kong felt that Ms. Ayoubi understood his goals and helped him accomplish them during the program.

He credits David Feldgofel, MHA, Associate Director of the Emergency Department at The Mount Sinai Hospital, as an important mentor during his internship. This relationship has continued as Mr. Feldgofel is now his direct supervisor. Mr. Kong also found the MHA program staff to be helpful during his time as a student.

“The community that Mount Sinai builds is unique compared to other schools. Everyone wants to see you succeed. Faculty help you create connections to people and resources from the Health System to enhance your studies.”

Mr. Kong believes the most valuable part of his experience was learning from professors that are working professionals, often within the Mount Sinai Health System. He appreciated their in-depth knowledge and ability to relate classroom concepts to real-life applications. His training in the MHA program is invaluable in his current role as Operations Supervisor in the Emergency Department, where he regularly applies concepts related to workflow optimization, process improvement, and cross-functional collaboration.

Flexibility was an important part of the program for Mr. Kong, since he continued his work at Gentile Retina while completing his MHA at Mount Sinai. He was able to finish the program in just one year.

“The Mount Sinai MHA program offers both online and in-person classes. This is extremely helpful for students working full-time. The flexibility here is great compared to other graduate programs.”

Mr. Kong completed the program in 2025 and is now the Operations Supervisor in the Emergency Department at The Mount Sinai Hospital. He heard about the role from Ms. Ellsworth. He began as an intern in the Emergency Department, where he noticed the workflows and processes could use improvement.

“Mount Sinai is great at providing student opportunities. We receive a lot of emails from faculty with available internships. That’s how I found the role within the Department of Emergency Medicine.”

He was able to help identify the root issues in the Emergency Department and take steps to rectify the problems. Mr. Kong utilized lessons from his MHA courses, particularly related to concepts such as project management and data analysis. He now understands how operational decisions within the Emergency Department fit into larger health system goals, allowing him to approach challenges with both patient outcomes and organizational performance in mind. In addition, he also learned how to partner and communicate with staff in the department, specifically to help them understand why operational changes are necessary and what the positive results will be for them.

Mr. Kong plans to continue working at the Emergency Department and developing his career further at Mount Sinai.

Learn more about the Master of Health Administration (MHA) program at Mount Sinai

Riding the New Wave of AI in Health Care

Updated on Jun 4, 2026 | Artificial Intelligence, Events, Featured, Research

The Icahn School of Medicine at Mount Sinai and the New York Academy of Sciences jointly hosted a conference, “The New Wave of AI in Health Care,” on May 12 and May 13, 2026.

The health care industry has overwhelmingly embraced artificial intelligence (AI) technology in all aspects—clinical, academic, administrative, and more—and with the breakneck speed of progress in this area, it’s little wonder the field is seeing an outpouring of innovation.

But innovation works best when all players collectively work together to create a wave that uplifts everyone.

“There is a real risk of creating silos. Competition, proprietary data, and intellectual property all pull institutions inward,” says Girish N. Nadkarni, MD, MPH, CPH, Chair of the Windreich Department of Artificial Intelligence and Human Health (AIHH) at the Icahn School of Medicine at Mount Sinai.

“But AI in health care punishes silos: a model trained on one hospital’s patients tends to fail at the next. Building something safe and generalizable forces you to collaborate,” says Dr. Nadkarni.

The speed at which AI developments occur makes it all the more important for everyone involved to convene. On Tuesday, May 12, and Wednesday, May 13, the Icahn School of Medicine and the New York Academy of Sciences jointly hosted a conference, “The New Wave of AI in Health Care.”

Girish N. Nadkarni, MD, MPH, CPH, Chair of the Windreich Department of Artificial Intelligence and Human Health at the Icahn School of Medicine at Mount Sinai, speaking at the The New Wave of AI in Health Care conference.

Over the two days, attendees gleaned the latest ways AI is being used to rethink health care delivery, clinical workflows, drug discovery, and patient experience and outcomes. More importantly, the event served as an opportunity for networking, creating the foundations for future collaboration. The event attracted clinicians, academics, industry professionals, and news media from around the world, with renowned institutions participating, including Mayo Clinic, Epic, AstraZeneca, and the National Institutes of Health (NIH).

Alexander Charney, MD, PhD, Vice Chair of the Windreich Department of Artificial Intelligence and Human Health, delivered the closing address during the conference.

“Oftentimes you go to conferences and the real experience is what happens between the talks—the one-on-one conversations you have with everyone,” said Alexander Charney, MD, PhD, Vice Chair of AIHH, during his closing remarks at the event.

The gathering of so many great minds together in one space to collectively ask questions about AI and solve problems in health care is inspiring, said Dr. Charney in his speech.

“At times, I was thinking about how people in the future would look at us today, and how people in the past would look at us today—in this room, dealing with this challenge of our time of how artificial intelligence is going to be used in health care and taking care of people,” he said. “And where I land on how we move forward, is that we should try and make both of those groups of people proud.”

What is this new wave of AI in the health care industry? Dr. Nadkarni, who hosted a keynote session, shares his perspective on the development of the field and his thoughts on the conference. A video recording of his session can also be viewed below.

Session VII: Keynote and Learning Health System. Session includes a fireside chat with former New York City Health Commissioner Dave Chokshi, MD, and a presentation from a member of NIH.

What is this “new wave of AI” we are seeing in health care? What makes it different from other technological waves we’ve seen before?

It’s not the first such wave—AI in medicine goes back to the expert systems of the 1970s and the machine learning wave of the last 15 years. What’s new is large, general-purpose, multimodal models at unprecedented scale. Earlier tools were narrow and brittle; this wave is general and fluent. The same model can read a note, interpret a scan, and reason across both. And it has crossed out of the lab into the clinic, touching the actual practice of medicine. That’s why it feels less like a better tool and more like a genuine shift.

How often do events such as this occur to bring innovators together? What would you say are some of the biggest values of such conferences?

They’re getting more frequent, but the ones that matter are still rare, because the hard part isn’t gathering people, it’s gathering the right mix. The value is putting clinicians, computer scientists, ethicists, regulators, and patients in one room. It separates signal from hype, builds the relationships that later become multisite studies, and forces the hard questions about equity and implementation onto the main stage. Honestly, the hallway conversations matter as much as the talks.

What does equity in health care AI look like, and how can we deliver the power of those tools to communities who need those solutions the most?

Equity doesn’t happen by default. Models built on well-resourced data tend to work worst for those already underserved. Conferences can help by refusing to treat that as an afterthought, by putting equity on the main stage, connecting innovators with safety-net and global-health partners—our work with the Guyana Ministry of Health is one example—and sharing tools openly so smaller institutions aren’t locked out.

AI’s real promise is scale. A validated model can reach a rural clinic as easily as an academic center, but only if we design for that from the start.

Over the two days of the The New Wave of AI in Health Care conference, speakers and panelists presented research and discussed the latest applications of AI in health care. Tanzeem Choudhury, PhD, from Cornell Tech, spoke in Session X: AI-Human Interactions and gave a presentation titled “The Future of Mental Health and AI – Perspective from Research, Entrepreneurship, and Implementation”.

The conference attracted leaders at the forefront of AI research in biomedical research and health care from around the world. John Halamka, MD, MS, from Mayo Clinic, delivered the opening keynote presentation in Session I: Welcome & State of the Art AI Models in Healthcare titled “Transforming Care Delivery Today—and What Comes Next”.

Representatives from Mount Sinai, including Robert Freeman, DNP, RN, Chief Digital Transformation Officer at the Mount Sinai Health System, spoke about AI innovations at the Health System. He hosted Session V: AI at the Bedside and Session VI: AI at the Bedside (Continued).

Benjamin Glicksberg, PhD, Director of the Center for AI in Children’s Health at the Icahn School of Medicine at Mount Sinai (second from right) seen in discussion during one of the various networking sessions held in between talks and presentations. These networking opportunities lay the foundation for collaboration between institutions.

Jeremy Hallett, MS, from University of Wisconsin-Madison, presenting during the poster session held at the end of the first day of the conference. The poster session featured research from 20 presenters.

The New Wave of AI in Health Care conference was made possible thanks to the joint efforts of the Icahn School of Medicine and the New York Academy of Sciences. Members of the organizing committee in this photo include, from left to right and back to front, Benjamin Glicksberg, PhD; Girish Nadkarni, MD, MPH; Alexander Charney, MD, PhD; Kelly Morgan, MHA; Ipek Ensari, PhD; Cassie Chartier, PhD; and Melanie Brickman Borchard, PhD, MSc.

What sort of pace should academic health systems like Mount Sinai be adopting for this wave of AI? Should systems like ours be at the forefront and setting directions?

Fast enough to lead, deliberate enough to be safe. Academic systems have the data, the patients, the rigor, and the mandate to generate evidence rather than just byproducts—so yes, we should be at the forefront. Our job is to set the standard and give the field a trustworthy template to follow. Leading here means leading on rigor and equity, not simply being first.

Lastly, in reflecting on Dr. Charney’s closing remarks, what are your thoughts on how the world of the past and the world of the future would think about what we’re doing with AI in health care today?

Clinicians a generation ago would be astonished that a machine can draft a note or read a scan—and probably wary about what it means for the human relationship at the center of medicine.

The future, I think, will judge us not on how clever our models were, but on whether we used them wisely, safely, and fairly, and kept the patient and clinician at the center. Echoing Dr. Charney, my hope is they’ll see this as the moment we chose to augment human care rather than replace it. We’re not just building tools—we’re setting precedents.

Video recordings of all sessions are available and can be viewed at these links

Day 1: Session I	Day 1: Session II and III	Day 1: Session IV and V	Day 1: Session VI and Closing
Day 2: Welcome and Session VII	Day 2: Session VIII	Day 2: Session IX	Day 2: Session X and Closing

MyPath: A New Approach to Improve Women’s Health Through Midlife and Beyond

May 28, 2026 | Featured, Women's Health, Your Health

Women’s health is complex—and it doesn’t often fit neatly into one appointment or one specialty. Many women experience distinct symptoms across life stages. They may wonder what’s going on, or where to turn next. Add the demands of work, family, and everyday life, and women may feel stretched thin and unheard.

“At the Carolyn Rowan Center for Women’s Health and Wellness, we offer a unique approach to women’s health called MyPath where care is organized around personalized pathways–integrated, coordinated, and holistic care designed to support your whole body and your whole life. Everything you need is here—guided, connected, and focused on you,” says Anna M. Barbieri, MD, Clinical Strategy Lead at the Carolyn Rowan Center for Women’s Health and Wellness.

“Our care pathways address transitions such as emotional health, sleep, energy, gynecologic health, and other layers of health that cannot be addressed in a single visit,” she adds.

“MyPath supports women through life’s transitions with clarity and empathy,” says Joanne L. Stone, MD, physician-scientist and Chair of Obstetrics, Gynecology and Reproductive Science at the Icahn School of Medicine at Mount Sinai.

“Each pathway brings together the right specialists at the right time, so your care feels intentional—not overwhelming,” she adds.

The first pathway focuses on one of the most important chapters of women’s health: the midlife transition, featuring perimenopause and menopause.

MyPath Balance 40+: Support for the Midlife Years

Midlife can bring hormonal shifts, sleep disruption, weight gain, stress, and new health concerns. MyPath Balance 40+ is a six-month, personalized care experience created to help women age 40 and over feel stronger, healthier, and more in control of their well-being.

Patients will receive coordinated support for:

Hormonal and metabolic health, including weight management
Heart and bone health
Sleep, mood, and stress
Pelvic and sexual health
Nutrition, movement, and overall vitality

“Your care unfolds step by step—starting with a comprehensive evaluation, followed by personalized treatment and ongoing support. So you always know what’s happening and why,” says Francesco Callipari, MD, Medical Director at the new Carolyn Rowan Center for Women’s Health and Wellness, and Assistant Clinical Professor and Vice Chair of Operations, Obstetrics, Gynecology and Reproductive Science at the Icahn School of Medicine at Mount Sinai.

“This approach is different because it’s not rushed, not fragmented, and because it’s designed around how women actually live,” he adds.

Looking Ahead

Additional MyPath programs will include MyPath Moms, MyPath Surgical Recovery, MyPath Healthspan, and MyPath Vitality 60+, each supporting women through different life stages.

Learn more about MyPath Balance 40+

Learn more about the Carolyn Rowan Center for Women’s Health and Wellness

« Older Entries